Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer.
Schmidt S, Bonilla WV, Reiter A, Stemeseder F, Kleissner T, Oeler D, Berka U, El-Gazzar A, Kiefmann B, Schulha SC, Raguz J, Habbeddine M, Scheinost M, Qing X, Lauterbach H, Matushansky I, Pinschewer DD, Orlinger KK. Schmidt S, et al. Among authors: lauterbach h. Oncoimmunology. 2020 Sep 15;9(1):1809960. doi: 10.1080/2162402X.2020.1809960. Oncoimmunology. 2020. PMID: 33457095 Free PMC article.
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.
Lauterbach H, Schmidt S, Katchar K, Qing X, Iacobucci C, Hwang A, Schlienger K, Berka U, Raguz J, Ahmadi-Erber S, Schippers T, Stemeseder F, Pinschewer DD, Matushansky I, Orlinger KK. Lauterbach H, et al. Front Oncol. 2021 Oct 14;11:732166. doi: 10.3389/fonc.2021.732166. eCollection 2021. Front Oncol. 2021. PMID: 34722273 Free PMC article. Review.
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys.
Boopathy AV, Sharma B, Nekkalapudi A, Wimmer R, Gamez-Guerrero M, Suthram S, Truong H, Lee J, Li J, Martin R, Blair W, Geleziunas R, Orlinger K, Ahmadi-Erber S, Lauterbach H, Makadzange T, Falkard B, Schmidt S. Boopathy AV, et al. Among authors: lauterbach h. NPJ Vaccines. 2023 Nov 10;8(1):175. doi: 10.1038/s41541-023-00768-x. NPJ Vaccines. 2023. PMID: 37945621 Free PMC article.
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment.
Raguz J, Pinto C, Pölzlbauer T, Habbeddine M, Rosskopf S, Strauß J, Just V, Schmidt S, Bidet Huang K, Stemeseder F, Schippers T, Stewart E, Jez J, Berraondo P, Orlinger KK, Lauterbach H. Raguz J, et al. Among authors: lauterbach h. J Immunother Cancer. 2024 Apr 17;12(4):e008286. doi: 10.1136/jitc-2023-008286. J Immunother Cancer. 2024. PMID: 38631709 Free PMC article.
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.
Gomar C, Di Trani CA, Bella A, Arrizabalaga L, Gonzalez-Gomariz J, Fernandez-Sendin M, Alvarez M, Russo-Cabrera JS, Ardaiz N, Aranda F, Schippers T, Quintero M, Melero I, Orlinger KK, Lauterbach H, Berraondo P. Gomar C, et al. Among authors: lauterbach h. J Immunother Cancer. 2024 Apr 16;12(4):e008287. doi: 10.1136/jitc-2023-008287. J Immunother Cancer. 2024. PMID: 38631714 Free PMC article.
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Hinterberger M, Giessel R, Fiore G, Graebnitz F, Bathke B, Wennier S, Chaplin P, Melero I, Suter M, Lauterbach H, Berraondo P, Hochrein H, Medina-Echeverz J. Hinterberger M, et al. Among authors: lauterbach h. J Immunother Cancer. 2021 Feb;9(2):e001586. doi: 10.1136/jitc-2020-001586. J Immunother Cancer. 2021. PMID: 33579736 Free PMC article.
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.
Hinterberger M, Endt K, Bathke B, Habjan M, Heiseke A, Schweneker M, Von Rohrscheidt J, Atay C, Chaplin P, Kalla M, Hausmann J, Schmittwolf C, Lauterbach H, Volkmann A, Hochrein H, Medina-Echeverz J. Hinterberger M, et al. Among authors: lauterbach h. Sci Rep. 2023 Mar 30;13(1):5162. doi: 10.1038/s41598-023-32060-2. Sci Rep. 2023. PMID: 36997583 Free PMC article.
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
Medina-Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, Kassub R, Gräbnitz F, Fiore G, Wennier ST, Chaplin P, Suter M, Hochrein H, Lauterbach H. Medina-Echeverz J, et al. Among authors: lauterbach h. Nat Commun. 2019 Nov 6;10(1):5041. doi: 10.1038/s41467-019-12998-6. Nat Commun. 2019. PMID: 31695037 Free PMC article.
92 results